Hyperpax
Brand names,
Hyperpax
Analogs
Hyperpax
Brand Names Mixture
Hyperpax
Chemical_Formula
C56H71N9O23S
Hyperpax
RX_link
http://www.rxlist.com/cgi/generic4/mycamine.htm
Hyperpax
fda sheet
Hyperpax
msds (material safety sheet)
Hyperpax
Synthesis Reference
No information avaliable
Hyperpax
Molecular Weight
1270.28 g/mol
Hyperpax
Melting Point
No information avaliable
Hyperpax
H2O Solubility
Freely soluble as sodium salt (> 200mg/mL)
Hyperpax
State
Solid
Hyperpax
LogP
No information avaliable
Hyperpax
Dosage Forms
Powder for solution (for injection)
Hyperpax
Indication
For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Hyperpax
Pharmacology
Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
Hyperpax
Absorption
No information avaliable
Hyperpax
side effects and Toxicity
Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
Hyperpax
Patient Information
No information avaliable
Hyperpax
Organisms Affected
Aspergillis, Candida and other fungi